Michael Hellerstein
Overview
Explore the profile of Michael Hellerstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
173
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang S, Guirakhoo F, Periasamy S, Ryan V, Wiggins J, Subramani C, et al.
Vaccines (Basel)
. 2024 Jan;
12(1).
PMID: 38250853
Antibodies provide critical protective immunity against COVID-19, and the Fc-mediated effector functions and mucosal antibodies also contribute to the protection. To expand the characterization of humoral immunity stimulated by subunit...
2.
Vroom M, Lu H, Lewis M, Thibodeaux B, Brooks J, Longo M, et al.
J Lipid Res
. 2024 Jan;
65(2):100497.
PMID: 38216056
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of disease burden in the world and is highly correlated with chronic elevations of LDL-C. LDL-C-lowering drugs, such as statins or monoclonal...
3.
Wang S, Wang C, Kuo H, Peng W, Huang J, Kuo B, et al.
Emerg Microbes Infect
. 2022 Oct;
11(1):2724-2734.
PMID: 36287714
The development of safe and effective vaccines to respond to COVID-19 pandemic/endemic remains a priority. We developed a novel subunit protein-peptide COVID-19 vaccine candidate (UB-612) composed of: (i) receptor binding...
4.
Wang C, Hwang K, Kuo H, Peng W, Shen Y, Kuo B, et al.
J Clin Invest
. 2022 Mar;
132(10).
PMID: 35316221
BackgroundThe Delta and Omicron variants of SARS-CoV-2 are currently responsible for breakthrough infections due to waning immunity. We report phase I/II trial results of UB-612, a multitope subunit vaccine containing...
5.
Salvato M, Domi A, Guzman-Cardozo C, Medina-Moreno S, Zapata J, Hsu H, et al.
Pathogens
. 2019 Aug;
8(3).
PMID: 31466243
Lassa fever surpasses Ebola, Marburg, and all other hemorrhagic fevers except Dengue in its public health impact. Caused by Lassa virus (LASV), the disease is a scourge on populations in...
6.
A Zika Vaccine Targeting NS1 Protein Protects Immunocompetent Adult Mice in a Lethal Challenge Model
Brault A, Domi A, McDonald E, Talmi-Frank D, McCurley N, Basu R, et al.
Sci Rep
. 2017 Nov;
7(1):14769.
PMID: 29116169
Zika virus (ZIKV) is a mosquito-borne flavivirus that has rapidly extended its geographic range around the world. Its association with abnormal fetal brain development, sexual transmission, and lack of a...
7.
Hellerstein M, Xu Y, Marino T, Lu S, Yi H, Wright E, et al.
Hum Vaccin Immunother
. 2012 Nov;
8(11):1654-8.
PMID: 23111169
Here, we report on GEO-D03, a DNA vaccine that co-expresses non-infectious HIV-1 virus-like particles (VLPs) and the human cytokine, granulocyte-macrophage colony-stimulating factor (GM-CSF). The virus-like particles display the native gp160...
8.
Pillai V, Hellerstein M, Yu T, Amara R, Robinson H
Vaccine
. 2008 Feb;
26(8):1136-41.
PMID: 18242791
Here we use tests for in vitro expression and in vivo immunogenicty to compare the biological activity of supercoiled and open circular forms of plasmid DNA vaccines. The different forms...
9.
Liu J, Hellerstein M, McDonnel M, Amara R, Wyatt L, Moss B, et al.
Vaccine
. 2007 Mar;
25(15):2951-8.
PMID: 17360078
Here, we conduct dose-response studies in mice for the elicitation of CD8 T cells by a DNA vaccine that expresses HIV Gag. For DNA doses ranging from 1 to 100...